WhatPeptide

5-Amino-1MQ

5-Amino-1MQ is a small-molecule NNMT inhibitor studied in preclinical obesity and metabolic syndrome models for its ability to reduce fat mass and improve metabolic parameters. It has shown promise in rodent studies for promoting leanness without apparent toxicity at research doses.

Preliminary evidence Unregulated Metabolic

Written by WhatPeptide Editorial Team · Last updated 2026-03-17

Non-peptide small molecule (NNMT inhibitor), not a peptide.

Half-life

Estimated 4-6 hours

Dosage range

50-100 mg daily (research context only)

Administration

Oral

Research level

Preliminary

How 5-Amino-1MQ works

5-Amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that regulates adipogenesis and energy metabolism by consuming SAM methyl groups. By blocking NNMT, the compound increases NAD+ and SAM availability in adipocytes, shifting cells toward energy expenditure and reducing lipid accumulation. This mechanism is distinct from GLP-1-based interventions and represents a novel metabolic target.

Also known as: 5-Amino-1-methylquinolinium, NNMT inhibitor

Research relevance

Fat Loss
Moderate relevance 70
Muscle Growth
Some relevance 40

Side effects & safety

Limited human safety data Potential off-target methylation effects

Contraindications

Pregnancy/breastfeeding
No established human safety profile

Consult a healthcare provider before use if any of these apply to you.

Key studies

FAQ

What is 5-Amino-1MQ? +
5-Amino-1MQ is a small-molecule NNMT inhibitor studied in preclinical obesity and metabolic syndrome models for its ability to reduce fat mass and improve metabolic parameters. It has shown promise in rodent studies for promoting leanness without apparent toxicity at research doses. Its mechanism of action is based on preliminary or early-stage research.
What is 5-Amino-1MQ researched for? +
5-Amino-1MQ has the strongest research relevance for Fat Loss, Muscle Growth. Evidence is based on preliminary or early-stage research.
What are the side effects of 5-Amino-1MQ? +
Reported side effects include Limited human safety data, Potential off-target methylation effects. Key contraindications: Pregnancy/breastfeeding; No established human safety profile.
Is 5-Amino-1MQ FDA approved? +
5-Amino-1MQ is not FDA-approved. It is available as a research compound or through compounding pharmacies in some jurisdictions.
How is 5-Amino-1MQ administered? +
5-Amino-1MQ is typically administered via oral route. Researched dosage range: 50-100 mg daily (research context only). Half-life: Estimated 4-6 hours.

Explore similar peptides

Adipotide

Preliminary evidence

Metabolic

A synthetic chimeric peptidomimetic (~2,611 Da) that destroys white adipose tissue vasculature. Its CKGGRAKDC homing motif binds prohibitin/annexin A2 on WAT blood vessels, while the D(KLAKLAK)₂ domain triggers mitochondrial apoptosis in those endothelial cells. Developed at UT MD Anderson; Phase 1 trial (NCT01262664) terminated with no published results.

NAD+

Moderate evidence

Metabolic

NAD+ is a critical coenzyme present in all living cells, central to cellular energy metabolism, DNA repair, and sirtuin-mediated longevity pathways. Circulating and intracellular NAD+ levels decline with age, and parenteral supplementation is studied for reversing age-related metabolic decline and improving mitochondrial function.

Tesofensine

Moderate evidence

Metabolic

A triple monoamine reuptake inhibitor (SERT IC₅₀ 11 nM, NET 1.7 nM, DAT 65 nM) of the phenyltropane family, originally developed by NeuroSearch for neurodegeneration. Acquired by Saniona (2014), sublicensed to Medix for Mexico/Argentina (2016). Phase 2: 0.5 mg achieved 9.2% placebo-subtracted weight loss (Astrup et al., Lancet 2008). Viking Phase 3 (372 patients, 24 weeks) completed Dec 2018. COFEPRIS favorable opinion Feb 2023 but approval withheld Nov 2024.